Does OCT Optimise Results of Stenting on the Left Main Stem (DOCTORS-LM)
Myocardial Infarction, Myocardial Ischemia, Non ST Segment Elevation Myocardial Infarction
About this trial
This is an interventional treatment trial for Myocardial Infarction focused on measuring left main stem, angioplasty, optical coherence tomography, myocardial infarction
Eligibility Criteria
Inclusion Criteria:
Patients aged 18 years or over presenting with:
- NSTEMI or unstable angina or stable angina or documented silent ischemia AND
- De novo angiographic lesion (% diameter stenosis >=50%) or functionally significant (FFR<=0.80) lesion of the left main stem (median or distal) with or without lesions of the ostia of the LAD and/or circumflex arteries (= Medina classification 1-0-0, 1-0-1, 1-1-0, 1-1-1) or ostial lesion of the LAD and/or circumflex artery requiring angioplasty with stent implantation that will cover the distal left main stem (=Medina classification 0-0-1, 0-1-0 ou 0-1-1) AND
- SYNTAX score ≤ 22 (or >22 and ≤32 and validated by the Heart Team)
- Lesion with reference angiographic diameter <=5.5mm
- Signature of written informed consent form.
Exclusion Criteria:
Patients with:
- ST segment elevation myocardial infarction
- Ostial lesion of the left main stem
- Technically impossible to perform OCT
- Creatinine clearance ≤ 30 ml/min/1.73m²
- Left ventricular ejection fraction <30%
- Hypotension or cardiogenic shock
- Unstable ventricular arrhythmia
- Contraindication to dual antiplatelet therapy for at least 6 (or 12) months (duration depending on the initial clinical presentation). Shorter dual antiplatelet therapy is possible in patients with long-term anticoagulation.
- Hypersensitivity or contraindication to any of the antithrombotic therapies used during or after the procedure
- Life expectancy <1 year
- Persons under judicial protection
- Subjects with no social security coverage
- Anticipated non-compliance with the study procedures
- Pregnant or lactating women
- Subjects within the exclusion period of another clinical trial
- Failure to provide written informed consent
Sites / Locations
- CHU Besancon
- CHRU Lille
- Hôpital Privé Saint Martin
- Centre Hospitalier de Chartres - Hôpital Louis Pasteur
- CHRU Clermont Ferrand
- Institut Cardiovasculaire Paris Sud
- CHU Nîmes - Hôpital Carémeau
- Institut Mutualiste Montsouris
- CHU Poitiers
- Clinique Saint Hilaire
- Institut Arnault Tzanck
- Hôpital Nord Franche-Comté
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
OCT group
Control group
OCT will be performed after initial coronary angiography and at the end of the procedure. Several OCT runs can be performed. The operator may change procedural strategy, and use additional interventions. The operator must evaluate the following parameters, based on OCT data: Before angioplasty: reference diameter and reference area of distal main vessel; lesion length; presence and extent of thrombus or calcification. Stent implantation: Stent should be sized according to distal reference diameter, and should allow for expansion to the reference diameter of the proximal main vessel. After stent implantation: minimal and reference lumen diameter, minimal and reference lumen area, minimal stent area, presence of thrombus, presence of edge dissection, tissue protrusion, optimal lesion coverage, malapposition, suboptimal stent deployment.
Angioplasty will be guided by traditional fluoroscopy alone, performed before and after stent implantation. The recommendation for angioplasty of left main stenosis is to use main vessel (MV) stenting with a proximal optimisation technique (POT) and provisional side branch (SB) stenting as a preferred approach. Predilatation of the side branch (SB) may be considered, but is recommended in the following circumstances: extensive ostial SB involvement, heavy calcification, etc. even with a provisional SB stenting approach.